{
    "clinical_study": {
        "@rank": "62165", 
        "arm_group": {
            "arm_group_label": "Inhaled Vidaza", 
            "arm_group_type": "Experimental", 
            "description": "Patients will receive inhaled VIDAZA once a day, Monday to Friday every other week and will continue the same treatment as long as they tolerate, or until disease gets worse. The starting dose will be 15 mg/m2."
        }, 
        "brief_summary": {
            "textblock": "This study will examine the effectiveness of a drug called Vidaza (azacitidine) giving in\n      inhalation form. To be eligible for the study, patients must have advanced stage non-small\n      cell lung cancer, and must have received at least one prior chemotherapy or targeted therapy\n      for their cancer."
        }, 
        "brief_title": "A Study of Inhaled Vidaza in Advanced Non-Small Cell Lung Lung Cancer Patients", 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Potential patients will go through screening process. Routine laboratory tests, CT scans,\n      pulmonary function tests and a bronchoscopy will be performed.\n\n      Eligible patients will take inhaled vidaza in the clinic daily, Monday to Friday, every\n      other week. After first cycle of treatment patients will get repeated bronchoscopy. Patients\n      will continue on study treatment until disease progression.\n\n      A total of 36 patients will take part in this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pathologically proven (either histologic or cytologic) diagnosis of Stage IV or\n             recurrent non-small cell lung cancer\n\n          -  Patient has received at least one prior standard chemotherapy or targeted therapy for\n             treatment of lung cancer.\n\n          -  ECOG Performance Status 0-1.\n\n          -  Age > 18.\n\n          -  Adequate baseline bone marrow reserve and organ function defined as\n\n               -  Absolute neutrophil count (ANC) >1,500 cells/ul\n\n               -  Platelets > 100,000 cells/ul\n\n               -  Hemoglobin > 9.0 g/dl\n\n               -  Serum creatinine < 1.5 x ULN\n\n               -  Total bilirubin < 2.0 times the institutional Upper Limit of Normal (ULN)\n\n               -  AST and ALT < 2.5 x the ULN\n\n          -  Adequate pulmonary reserve defined as adequate airflow defined by a measured Forced\n             Expiratory Volume (FEV1) not less than 50% of the predicted value and adequate\n             pulmonary reserve as evidenced by a FEV1/FVC ratio of 65% or greater).\n\n          -  Patient must sign study specific informed consent prior to study entry.\n\n          -  Women of childbearing potential must have:\n\n               -  A negative serum or urine pregnancy test (sensitivity 25IU HCG/L) within 72\n                  hours prior to the start of study drug administration\n\n               -  Persons of reproductive potential must agree to use and utilize an adequate\n                  method of contraception throughout treatment and for at least 4 weeks after\n                  study drug is stopped prior to study enrollment, women of childbearing potential\n                  must be advised of the importance of avoiding pregnancy during trial\n                  participation and the potential risk factors for an unintentional pregnancy.\n\n        Exclusion Criteria:\n\n          -  Patients with prior chest or mediastinal radiotherapy\n\n          -  Concomitant disease or condition that could interfere with the conduct of the study,\n             or that would, in the opinion of the investigator, pose an unacceptable risk to the\n             patient in this study.\n\n          -  Contraindication to or unwillingness to undergo study related procedures including a\n             repeat bronchoscopy.\n\n          -  Participation in an investigational drug or device study or treatment with any\n             anti-neoplastic agent within 14 days of the first day of dosing on this study\n\n          -  History of significant bleeding disorder unrelated to cancer, including:\n\n               -  Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)\n\n               -  Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor\n                  VIII antibodies)\n\n          -  Unwillingness or inability to comply with the study protocol for any other reason.\n\n          -  Women who:\n\n               -  are unwilling or unable to use an acceptable method to avoid pregnancy for the\n                  entire study period and for at least 4 weeks after cessation of study drug, or\n\n               -  have a positive pregnancy test at baseline, or\n\n               -  are pregnant or breastfeeding\n\n          -  Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for\n             treatment of either a psychiatric or physical (e.g., infectious) illness."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02009436", 
            "org_study_id": "2013-382"
        }, 
        "intervention": {
            "arm_group_label": "Inhaled Vidaza", 
            "intervention_name": "Inhaled Vidaza", 
            "intervention_type": "Drug", 
            "other_name": "Nebulized azacitidine"
        }, 
        "intervention_browse": {
            "mesh_term": "Azacitidine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Lung Cancer", 
            "Vidaza", 
            "Inhaled", 
            "Inhalation", 
            "Nebulized", 
            "chemotherapy", 
            "gene", 
            "gene expression", 
            "suppressor gene", 
            "epigenetic"
        ], 
        "lastchanged_date": "June 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bronx", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10461"
                }, 
                "name": "Montefiore Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "Steven Keller, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Roman Perez-Soler, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Rasim Gucalp, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Missak Haigentz, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Chengchang Zhu, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Yiyu Zou, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Study of Inhaled Vidaza\u00ae in Patients With Advanced NSCLC.", 
        "other_outcome": [
            {
                "description": "Pharmacokinetic parameter data such as Cmax, tmax, Volume distribution, Clearance and Bioavailability will be collected.", 
                "measure": "Pharmacokinetic parameters of inhaled Vidaza", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Determination of changes in global methylation patterns in the bronchial epithelium (bronchial tissue samples) pre and post treatment.", 
                "measure": "DNA Methylation patterns", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Efficacy of inhaled Vidaza on intra-thoracic tumors radiologically.", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "The length of time during and after study enrollment which cancer does not get worse radiologically. Evaluations will be performed every 8 weeks.", 
                "measure": "Progression free survival.", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "The length of time during and after study enrollment which tumor in the thorax does not get worse radiologically. Evaluations will be performed every 8 weeks.", 
                "measure": "Intra-thoracic tumor progression free survival", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Overall survival rate", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "overall_contact": {
            "email": "sforde@montefiore.org", 
            "last_name": "Shakira Forde", 
            "phone": "1-718-379-6862"
        }, 
        "overall_contact_backup": {
            "email": "kristin.fallon-hanley@einstein.yu.edu", 
            "last_name": "Kristin Fallon-Hanley, MBA", 
            "phone": "718-379-6867"
        }, 
        "overall_official": {
            "affiliation": "Montefiore Cancer Center, Albert Einstein College of Medicine", 
            "last_name": "Bilal Piperdi, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Data and Safety Monitoring Board", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of patients that will tolerate the treatment with inhalation of Vidaza when given with a nebulizer.", 
                "safety_issue": "Yes", 
                "time_frame": "2 months"
            }, 
            {
                "measure": "Number of adverse events when patients are treated with inhaled Vidaza.", 
                "safety_issue": "Yes", 
                "time_frame": "2 months"
            }, 
            {
                "description": "Severity of reported adverse events will be evaluated using CTCAE v4.0", 
                "measure": "Severity of adverse events when patients are treated with inhaled Vidaza.", 
                "safety_issue": "Yes", 
                "time_frame": "2 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02009436"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Albert Einstein College of Medicine of Yeshiva University", 
            "investigator_full_name": "Bilal Piperdi", 
            "investigator_title": "Associate Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Dose of Inhaled Vidaza will be increased or decreased based on the results, obtained during the study. Minimum effective dose will be determined and is defined as the minimum dose of inhaled Vidaza required to re-activate five candidate tumor suppressor genes.", 
            "measure": "Minimum effective dose of inhaled Vidaza required to induce the re-expression of relevant 5 candidate tumor suppressor genes.", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "source": "Albert Einstein College of Medicine of Yeshiva University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Albert Einstein College of Medicine of Yeshiva University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}